Skip to main content

News HP

Mon, 07/02/2018 - 15:00 - Fri, 07/02/2021 - 15:30
  • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
  • Anti-CD160 is a potent inhibitor of ocular v
Mon - 07, 11/05 - 07/2018 - 09:00

Do not hesitate to contact us if you want to meet our team during Bio-Eu

Fri, 04/20/2018 - 08:30

Not to be distributed directly or indirectly in the United States, Canada, Australia or Japan

 

Thu, 04/05/2018 - 09:00
  • ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to c

Tue, 11/03/2015 - 17:00

IM Europe and Sofimac Partners are the main investors

 

Thu, 09/10/2015 - 17:00

Supported by ElsaLys Biotech, PX’Therapeutics, a subsidiary of the Aguettant group, and Centr

Thu, 07/02/2015 - 17:00
  • Developed so far by MABLIFE in ophthalmology, the anti-CD160 antibody has also a significant therapeutic potential in oncology.

Tue, 02/16/2016 - 17:00
  • Having acquired in June 2015 the assets of CD160 in the field of ophthalmology, ElsaLys Biotech strengthens its intellectual property an

Thu, 12/15/2016 - 17:00
  • Initially developed by TRANSGENE, one of ELSALYS BIOTECH’s founding shareholders, this antibody inhibits a deleterious subpopulation of

Mon, 01/30/2017 - 17:00

After having recently enriched its pipeline of therapeutic antibodies in oncology, ElsaLys Biotech strengthens its management team with the arriva

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.